Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | GRN | P28799 | 4/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.36 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12668137 | 0.85 | GRN (0.36) | KDM4EGRNSORT1ALDH1A1SRD5A2 | |
| SCHEMBL14755582 | 0.82 | NNMT (0.53) | KDM4EGRNSORT1ALDH1A1TSHR | |
| SCHEMBL30505631 | 0.79 | ASPH (0.38) | KDM4EALDH1A1ALOX15TSHRTDP1 | |
| SCHEMBL1111665 | 0.79 | ASPH (0.38) | KDM4EALDH1A1ALOX15TSHRTDP1 | |
| SCHEMBL698657 | 0.79 | KDM4E (0.52) | KDM4EALDH1A1ALOX15TSHRTDP1 | |
| SCHEMBL13230300 | 0.79 | MAPK1 (0.44) | KDM4ETSHRTDP1L3MBTL1MAPK1 | |
| SCHEMBL12775329 | 0.79 | RAB9A (0.37) | ALDH1A1L3MBTL1LMNA | |
| SCHEMBL17808318 | 0.77 | LMNA (0.39) | KDM4EALDH1A1L3MBTL1MAPK1LMNA | |
| SCHEMBL47578 | 0.76 | TSHR (0.38) | KDM4EGRNSORT1ALDH1A1TSHR | |
| SCHEMBL12775490 | 0.74 | CNR1 (0.41) | KDM4EALDH1A1ALOX15TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863766-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-05-20 | — | — | EP | claimed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | claimed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| EP-3802517-B1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-12-21 | — | — | EP | disclosed |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-12 | — | — | US | disclosed |
| US-10442828-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| US-20170291917-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170291917-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-1863766-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | CGI PHARMACEUTICALS, INC (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2068849-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | BTK, LYN, LCK | KDM4E 1333/4885GRN 3943/4885SORT1 4362/4885 |
| US-10442828-B2 | Kinase inhibitors | SYK, LTK, LTB4R | KDM4E 2216/4885GRN 4634/4885SORT1 2244/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | KDM4E 868/4885GRN 4368/4885SORT1 4630/4885 |
| US-20170291917-A1 | KINASE INHIBITORS | SYK, LYN, BTK | KDM4E 2053/4885GRN 2580/4885SORT1 3255/4885 |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | LPAR1, LPAR3, LPAR2 | KDM4E 2727/4885GRN 3796/4885SORT1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.